公开(公告)号：US12144825B2

公开(公告)日：2024-11-19

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David Sourdive ,  Aymeric Duclert ,  Mathieu Simon ,  Philippe Duchateau ,  Alan Marc Williams ,  Laurent Poirot

IPC: A61K35/17 ,  A61K39/00 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US11690873B2

公开(公告)日：2023-07-04

申请号：US16498276

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Cecile Schiffer-Mannioui ,  Philippe Duchateau ,  Anne-Sophie Gautron

IPC: C07K14/705 ,  C07K19/00 ,  A61P35/00 ,  A61K39/395 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US10508289B2

公开(公告)日：2019-12-17

申请号：US15031996

申请日：2014-10-24

Applicant: CELLECTIS, S.A.

Inventor： Philippe Duchateau ,  Alexandre Juillerat

IPC: C12N15/90 ,  C12N9/22 ,  A61K48/00 ,  C07K14/195 ,  A61K38/00

Abstract: The present invention is in the field of genetic editing tools and methods of genetic engineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called “triplet repeat diseases”, such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.

公开(公告)号：US10472613B2

公开(公告)日：2019-11-12

申请号：US15517708

申请日：2015-10-07

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot

IPC: C07K14/705 ,  C12N5/16 ,  C07K14/725 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/07 ,  C12N15/02 ,  C12N15/87

Abstract: The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.

公开(公告)号：US20190316100A1

公开(公告)日：2019-10-17

申请号：US16237901

申请日：2019-01-02

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva

IPC: C12N9/16 ,  C12P19/34 ,  C07K14/47 ,  C12N9/22

Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.

公开(公告)号：US10378007B2

公开(公告)日：2019-08-13

申请号：US14424757

申请日：2013-08-30

Applicant: CELLECTIS, S.A.

Inventor： Alexandre Juillerat ,  Philippe Duchateau

IPC: C12N15/10 ,  C07K14/195 ,  C07H21/00 ,  C12N15/82 ,  C12N15/63

Abstract: Methods for improving or modulating targeting specificity of TALE proteins by introducing alternative RVDs into their modular nucleic acid binding domains. Polynucleotides encoding TALE proteins having alternative targeting specificity towards a nucleic acid target sequence. TALE proteins having alternative targeting specificity towards a nucleic acid target sequence and methods of making and using them.

公开(公告)号：US20170067022A1

公开(公告)日：2017-03-09

申请号：US15120060

申请日：2015-02-20

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  Philippe Duchateau

IPC: C12N5/0783 ,  A61K35/17 ,  C07K16/28 ,  C07K14/47 ,  C07K14/725 ,  C07K14/715

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C07K14/4703 ,  C07K14/7051 ,  C07K14/7155 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2317/622 ,  C07K2319/74 ,  C12N5/0636 ,  C12N9/16 ,  C12N2501/60 ,  C12N2510/00

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighbouring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

Abstract translation: 本发明涉及工程化T细胞，其制备方法及其作为药物的用途，特别是用于免疫治疗。 本发明的工程化T细胞被设计为表达针对在恶性或感染细胞表面表达的至少一种抗原的嵌合抗原受体（CAR）和调节性T细胞（Treg）的分泌抑制剂。 优选地，这种分泌的抑制剂是叉头/翼状螺旋转录因子3（FoxP3）的肽抑制剂，其涉及T细胞分化成调节性T细胞的特异性因子。 本发明的工程化T细胞将其免疫活性指向特定的恶性或感染细胞，同时将阻止相邻的调节性T细胞调节免疫应答。 本发明开启了标准和负担得起的过继性免疫治疗策略的方式，特别是治疗或预防癌症以及细菌或病毒感染。

公开(公告)号：US11692169B2

公开(公告)日：2023-07-04

申请号：US16939466

申请日：2020-07-27

Applicant: Cellectis

Inventor： Philippe Duchateau ,  Laurent Poirot

IPC: C12N5/0783 ,  A61K35/17 ,  A61P35/02 ,  A61P35/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02 ,  C12N2501/599 ,  C12N2510/00 ,  Y02A50/30

Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

公开(公告)号：US11136566B2

公开(公告)日：2021-10-05

申请号：US16237901

申请日：2019-01-02

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva

IPC: C12N9/16 ,  C12N15/63 ,  C12N5/071 ,  C12N5/10 ,  C07K14/195 ,  C12N9/22 ,  C07K14/47 ,  A61K38/00 ,  C12P19/34

Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.

公开(公告)号：US10584352B2

公开(公告)日：2020-03-10

申请号：US15891496

申请日：2018-02-08

Applicant: Cellectis

Inventor： Philippe Duchateau ,  André Choulika ,  Laurent Poirot

IPC: A61K35/17 ,  C12N15/85 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90 ,  C12N15/113

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.